SCHEMBL279739

SCHEMBL279739

Cc1ccc(C(=O)CSc2ccncn2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
HTT P42858 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 8/20 0.44
NPC1 O15118 7/20 0.44
NPSR1 Q6W5P4 1/20 0.42
PKM P14618 1/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALOX15 P16050 1/20 0.40
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
DAO P14920 1/20 0.39
POLB P06746 2/20 0.38
TDP1 Q9NUW8 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13060968 0.80 RAB9A (0.50) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL280130 0.73 NPC1 (0.44) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL280148 0.73 ADORA2A (0.43) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL280137 0.73 ADORA2A (0.44) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL280361 0.69 RAB9A (0.47) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL279942 0.69 HSD17B10 (0.49) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL280052 0.69 MAPT (0.41) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL279938 0.69 ADORA2A (0.36) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL279741 0.68 HSD11B1 (0.49) ALDH1A1HPGDMAPTRAB9ANPC1
SCHEMBL280368 0.68 KMT2A (0.44) ALDH1A1HPGDHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL ALDH1A1 2047/4885HPGD 1895/4885HTT 1630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.